Phase II trial of nolatrexed dihydrochloride [Thymitaq™, AG 337] in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 25, Issue 1, 2007, Pages 85-94

  Jhawer, Minaxi ^a   Rosen, Lee ^b   Dancey, Janet ^c   Hochster, Howard ^d   Hamburg, Solomon ^e   Tempero, Margaret ^f   Clendeninn, Neil ^g   Mani, Sridhar ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Premiere Oncology   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Twr Hematology Oncology Medical Group   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE

Author keywords

Hepatocellular carcinoma; Phase II clinical trial; Thymidylate synthase inhibitors; Thymitaq

Indexed keywords

ANTIEMETIC AGENT; CIMETIDINE; NOLATREXED; ONDANSETRON; WARFARIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEMOGRAPHY; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; FEVER; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; MACULOPAPULAR RASH; MALE; MOUTH ULCER; NAUSEA AND VOMITING; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VAGINAL ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; QUINAZOLINES; STOMATITIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750489731     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9003-x     Document Type: Article

References (37)

1. American Cancer Society (2005) Cancer facts and figures 2005. American Cancer Society, Atlanta, GA
2. Thomas M, Zhu A (2005) Hepatocellular carcinoma: The need for progress. J Clin Oncol 23(13):2982-2899
3. Physician's Data Query (1993) Adult primary liver cancer (computer program). National Cancer Institute
4. Lotze MT, Flickinger JC, Carr BI (1993) Hepatobiliary neoplasms. In: De Vita VT, Hellman S (eds) Cancer principles and practice of oncology. JB Lippincott, Philadelphia pp 883-913
5. Tsukuma H, Hiyama T, Tanaka S (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801
6. Parkin DM, Whelan SL, Ferlay J et al (eds) (1997) Cancer incidence in five continents, vol VII. International agency for research on cancer, Lyon, France
7. A new prognostic system for hepatocellular carcinoma (1998) A retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751
8. Di Bisceglie AM, Carithers Jr RL, Gores GJ (1998) Hepatocellular carcinoma. Hepatology 28(4):1161-1165
9. Sitzmann JV, Order SE, Klein JL (1987) Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer. J Clin Oncol 5:1566-1573
10. Venook A (1994) Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 12:1324-1334
11. Ihde DC, Kane RC, Cohen MH (1977) Adriamycin therapy in American patients with hepatocellular carcinoma. Can Treat Rep 61:1385
12. Tetef M, Doroshow J, Akman S (1995) 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. Cancer Invest 13:460
13. Yang TS, Lin YC, Chen JS (2000) Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 89:750
14. Yang TS, Chang WC, Lin YC (2003) A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma (abstract). Proc Am Soc Clin Oncol 22:336a
15. Lee J, Park JO, Kim WS (2004) Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol 54:385
16. Yeo W, Mok TS, Zee B (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532
17. Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, Aherne GW (2000) Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Can Res 6:2538-2546
18. Webber SE, Bleckman TM, Attard J (1993) Design of thymidylate synthase inhibitors using protein crystal-structures - The synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem 36:733-746
19. Webber S, Bartlett CA, Boritzki TJ, Hilliard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA, Shetty BV (1996) AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Can Chemother Pharmacol 37:509-517
20. Rafi I, Taylor GA, Calvette JA (1995) Clinical pharmacokinetic and pharmacodynamic studies with the non-classical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG 337) given by 24 hour continuous intravenous infusion. Clin Cancer Res 1:275-1284
21. Rafi I, Boddy AV, Calvete JA, Taylor GA et al (1998) Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Oncol 160:1131-1141
22. Loh KK, Cohn A, Kelly K (1996) Phase II trials of thymitaq (AG337) in six solid tumor diseases. Proc Am Soc Clin Onc 15:183
23. Belani CP, Agarwal S, Johnson J, Cohn A, Bernstein J, Langer C (1997) A phase II clinical trial of Thymitaq (AG337) in patients with squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 16:1381a
24. Stuart KE, Hajdenberg J, Cohn A (1996) A phase II trial of thymitaq (AG337) in patients with hepatocellular carcinoma. Proc Am Soc Clin Onc 15:202
25. Eximias Pharmaceutical Corporation, Investigator's Brochure (2005) Version VII
26. World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. World health organization, Geneva, Switzerland
27. The Cancer Therapy Evaluation Program: Common toxicity criteria manual, 8/99 update. http://ctep.info.nih.gov/CTC3/CTC-Manual.htm
28. Gehan EA (1961) The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353
29. Simon R (1987) How large should a phase II trial of a new drug be? Cancer Treat Rep 71:1079-1085
30. Bland MJ, Altman DG (1998) Survival probabilities the Kaplan-Meier method. BMJ 317:1572-1580
31. Rafi BV, Calvete JA, Newell DR, Bailey NP, Lind MJ, Green M, Hines J, Johnstone A, Clendeninn N, Calvert AH (1998) Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors. J Clin Onco 116(3):1131-1134
32. Falkson G, Moertel CG, Lavin P (1978) Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149
33. Choi TK, Lee NW, Wong J (1984) Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. Cancer 53:401
34. Melia WM, Johnson PJ, Williams R (1983) Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 51:206
35. Czauderna P, Mackinlay G, Perilongo G (2002) Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 20:2798
36. Drori S, Jansen G, Mauritz R, Peters G, Assaraf Y (2000) Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. J Bio Chem 275(40):30855-30863
37. Porta C, Ruff P, Feld R, Feun L, Jeziorski K, Leighton J, Senico P, Gallo J, Kennealey G (2005) Results of a phase III randomized controlled study, the largest ever completed in Hepatocellular Carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with Nolatrexed (NOL) or Doxorubicin (DOX). Presented at GI ASCO